# ImageneBio, Inc. (IMA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $5.51 (-0.72%)

> ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases. The company is driven by the mission to transform patient outcomes through innovative medicines that aim to not only control symptoms but also alter the course of serious immune-related conditions. Leveraging both external innovation and its proprietary QuadraTek® platform, ImageneBio is focused on creating differentiated therapies with optimized safety, efficacy, and convenience profiles. Its lead product candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that has progressed through Phase 2a clinical trials targeting atopic dermatitis and alopecia areata. The company's research and development pipeline is engineered to address a broad spectrum of immune and inflammatory indications, supporting its goal to pioneer next-generation treatments for underserved patient populations. Founded in 2016 and headquartered in San Diego, ImageneBio plays a significant role in the biotechnology sector by striving to improve quality of life for those affected by chronic immunological and inflammatory diseases.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $800,000 | — | -$48M | -$45M | $-9.64 |
| 2024 | $4M | — | -$37M | -$37M | $-22.10 |
| 2023 | $9M | — | -$75M | -$68M | $-1.63 |
| 2022 | $16M | — | -$71M | -$69M | $-1.90 |
| 2021 | $31M | — | -$34M | -$34M | $-1.22 |
| 2020 | $9M | — | -$45M | -$44M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $153M | $20M | $133M | $95M | — |
| 2024 | $16M | $17M | -$161M | $12M | — |
| 2023 | $192M | $22M | -$126M | $120M | — |
| 2022 | $172M | $25M | $147M | $60M | — |
| 2021 | $248M | $40M | $208M | $232M | — |
| 2020 | $168M | $63M | -$101M | $162M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$48M | — | — |
| 2024 | -$21M | — | — |
| 2023 | -$80M | $414,000 | -$80M |
| 2022 | -$74M | $1M | -$76M |
| 2021 | -$60M | $2M | -$62M |
| 2020 | -$38M | $766,000 | -$39M |

Source: [CompaniesByCap](https://companiesbycap.com/company/IMA)